鈥?Development History
On December 31, 1993, Hangzhou Jiuyuan Gene Engineering Co., Ltd. was registered and established in Hangzhou New High-tech Development Zone.
On October 14, 1996,the company obtained the Trial-production Approval Number and New Drug Certificate of JILIFEN, the first rhG-CSF injection in China, making China become the third country able to manufacture the drug in large volumes following in the U.S and Japan.
In June, 1998, the drug low molecular weight heparin sodium injection (JIPAILIN) was approved for production and marketing by Ministry of Health.
On September 18, 2003,the company achieved a New Drug Certificate and Manufacture Approval of JIJUFEN, a platelet promoting drug (Recombinant Human Interleukin 11).
In July, 2006, the company initiated the production and sales of the 4th product YINUOJIA (Enoxaparin Sodium Injection), indicating the first officially approved enoxaparin was born in China.
The company was awarded as one of the first "National High-Tech Enterprises" in 2008.
On December 19, the 5th product JIOUTING (Palonosetron Hydrochloride API and injection) officially got approval for manufacture.
In 2010, the new product recombinant human bone repair material BMP-2 (GUYOUDAO) was manufactured and launched on market.
In October, 2013,the company reformed marketing system and established a development strategy of "Marketing First, Total Marketing".
In 2018, the company has initiated a major transformation, focusing on both innovative and generic drugs.
In 2020, R&D center moved to Hangzhou Medicine valley. The company's sales exceeded 1 billion yuan.
鈥?Company Profile
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is a modern biopharmaceutical company, specialized in R&D, manufacture and sales of gene engineering, biochemical, chemical drugs and medical device. The company was founded in December 1993 as a member of Huadong Medicine Group, and became one of t
[Indication]
1. Treatment of established deep veihromboembolic with or without pulmonary embolism.
3. Prevention of thrombus formation in the extra-corporal circulation during hemodialysis. and cultural activit1ies of the Communist Party, the company makes all efforts to promote the construction of corporate culture and build a learning and focused efficient team.rhIL-11 injection 0.75mg manufacturers
website:http://www.jiuyuangene.net/
On December 31, 1993, Hangzhou Jiuyuan Gene Engineering Co., Ltd. was registered and established in Hangzhou New High-tech Development Zone.
On October 14, 1996,the company obtained the Trial-production Approval Number and New Drug Certificate of JILIFEN, the first rhG-CSF injection in China, making China become the third country able to manufacture the drug in large volumes following in the U.S and Japan.
In June, 1998, the drug low molecular weight heparin sodium injection (JIPAILIN) was approved for production and marketing by Ministry of Health.
On September 18, 2003,the company achieved a New Drug Certificate and Manufacture Approval of JIJUFEN, a platelet promoting drug (Recombinant Human Interleukin 11).
In July, 2006, the company initiated the production and sales of the 4th product YINUOJIA (Enoxaparin Sodium Injection), indicating the first officially approved enoxaparin was born in China.
The company was awarded as one of the first "National High-Tech Enterprises" in 2008.
On December 19, the 5th product JIOUTING (Palonosetron Hydrochloride API and injection) officially got approval for manufacture.
In 2010, the new product recombinant human bone repair material BMP-2 (GUYOUDAO) was manufactured and launched on market.
In October, 2013,the company reformed marketing system and established a development strategy of "Marketing First, Total Marketing".
In 2018, the company has initiated a major transformation, focusing on both innovative and generic drugs.
In 2020, R&D center moved to Hangzhou Medicine valley. The company's sales exceeded 1 billion yuan.
鈥?Company Profile
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is a modern biopharmaceutical company, specialized in R&D, manufacture and sales of gene engineering, biochemical, chemical drugs and medical device. The company was founded in December 1993 as a member of Huadong Medicine Group, and became one of t
[Indication]
1. Treatment of established deep veihromboembolic with or without pulmonary embolism.
3. Prevention of thrombus formation in the extra-corporal circulation during hemodialysis. and cultural activit1ies of the Communist Party, the company makes all efforts to promote the construction of corporate culture and build a learning and focused efficient team.rhIL-11 injection 0.75mg manufacturers
website:http://www.jiuyuangene.net/
鈥?Development History
On December 31, 1993, Hangzhou Jiuyuan Gene Engineering Co., Ltd. was registered and established in Hangzhou New High-tech Development Zone.
On October 14, 1996,the company obtained the Trial-production Approval Number and New Drug Certificate of JILIFEN, the first rhG-CSF injection in China, making China become the third country able to manufacture the drug in large volumes following in the U.S and Japan.
In June, 1998, the drug low molecular weight heparin sodium injection (JIPAILIN) was approved for production and marketing by Ministry of Health.
On September 18, 2003,the company achieved a New Drug Certificate and Manufacture Approval of JIJUFEN, a platelet promoting drug (Recombinant Human Interleukin 11).
In July, 2006, the company initiated the production and sales of the 4th product YINUOJIA (Enoxaparin Sodium Injection), indicating the first officially approved enoxaparin was born in China.
The company was awarded as one of the first "National High-Tech Enterprises" in 2008.
On December 19, the 5th product JIOUTING (Palonosetron Hydrochloride API and injection) officially got approval for manufacture.
In 2010, the new product recombinant human bone repair material BMP-2 (GUYOUDAO) was manufactured and launched on market.
In October, 2013,the company reformed marketing system and established a development strategy of "Marketing First, Total Marketing".
In 2018, the company has initiated a major transformation, focusing on both innovative and generic drugs.
In 2020, R&D center moved to Hangzhou Medicine valley. The company's sales exceeded 1 billion yuan.
鈥?Company Profile
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is a modern biopharmaceutical company, specialized in R&D, manufacture and sales of gene engineering, biochemical, chemical drugs and medical device. The company was founded in December 1993 as a member of Huadong Medicine Group, and became one of t
[Indication]
1. Treatment of established deep veihromboembolic with or without pulmonary embolism.
3. Prevention of thrombus formation in the extra-corporal circulation during hemodialysis. and cultural activit1ies of the Communist Party, the company makes all efforts to promote the construction of corporate culture and build a learning and focused efficient team.rhIL-11 injection 0.75mg manufacturers
website:http://www.jiuyuangene.net/
0 Comments
0 Shares
